Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00684255 · ClinicalTrials.gov registry record · Phase 1
Reduced Intensity Transplant in Medically Refractory Systemic Lupus Erythematosus (SLE) and Systemic Sclerosis (SSc)
A Phase 1 study, sponsored by New York Medical College.
- Terminated
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT00684255 is a Phase 1 study that was terminated before completion, run by New York Medical College. The registered enrollment target is 1 participants.
The verdict
NCT00684255, a Phase 1 study, was terminated before completion, sponsored by New York Medical College.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if a reduced intensity (RI) (non-myeloablative) chemoimmunotherapy followed by Allogeneic Stem Cell Transplantation AlloSCT (matched family donors and matched unrelated cord blood donors) will be well tolerated.
Interventions
- DRUG Fludarabine
- DRUG Busulfan
- DRUG Campath
- PROCEDURE Reduced Intensity Allogeneic Transplant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2007-08 |
| Est. Completion | 2008-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00684255
The ClinicalTrials.gov registry entry for NCT00684255 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New York Medical College, which has 47 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Fludarabine is the first listed.
NCT00684255 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00684255 about?
NCT00684255 is a clinical study titled "Reduced Intensity Transplant in Medically Refractory Systemic Lupus Erythematosus (SLE) and Systemic Sclerosis (SSc)". The purpose of this study is to determine if a reduced intensity (RI) (non-myeloablative) chemoimmunotherapy followed by Allogeneic Stem Cell Transplantation AlloSCT (matched family donors and matched unrelated cord blood donors) will be well tolerated.
What is the current status of trial NCT00684255?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2007-08. Estimated completion is 2008-07.
What interventions are being tested in trial NCT00684255?
The interventions under investigation include: Fludarabine (DRUG), Busulfan (DRUG), Campath (DRUG), Reduced Intensity Allogeneic Transplant (PROCEDURE).
Who is sponsoring clinical trial NCT00684255?
This trial is sponsored by New York Medical College, which has 47 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.